SAGE meeting of 5 - 7 April 2011
Presentations
Report from IVB Director
-
Report from IVB Director
pdf, 5.60Mb
J-M. Okwo-Bele
Regional priorities, major policy and implementation issues: reports from AFR, EMR and SEAR
AFR
-
Report from AFR
pdf, 3.59Mb
D. Nshimirimana
EMR
-
Report from EMR
pdf, 5.05Mb
N. Teleb
SEAR
-
Report from SEAR
pdf, 671kb
N. Abeysinghe
Report from the GAVI Alliance secretariat
-
GAVI report
pdf, 2.31Mb
N. Schwalbe
Reports from other Advisory Committees in Immunization
-
Report from the Advisory Committee of the Initiativ (IVAC)
pdf, 1.15Mb
P. Ndumbe -
Report of the Global Advisory Committee on Vaccine Safety (GACVS)
pdf, 1.04Mb
P. Smith
Pandemic and seasonal influenza vaccines
-
International Health Regulations Review Committee (IHR): conclusions and recommendations
pdf, 1.16Mb
H. Fineberg -
H1N1 update: - use of deployed vaccine
pdf, 4.50Mb
L. Hedman -
H1N1 update: - epidemiology
pdf, 1.93Mb
T. Mounts -
SAGE Working Group on influenza vaccines and immunization. Update on process
pdf, 282kb
L. Miller
Tick-borne encephalitis
-
Introduction: context and process
pdf, 1.30Mb
J. Hombach -
Disease epidemiology & burden of disease
pdf, 5.15Mb
J. Süss -
Vaccine effectiveness and safety
pdf, 1.31Mb
H. Kollaritsch -
Draft recommendations on the use of tick-borne encephalitis vaccines
pdf, 390kb
J. Eskola
Meningococcal meningitis vaccines
-
Update on the epidemiology of meningococcal disease
pdf, 3.40Mb
N. Messonnier -
Availability, safety and effectiveness of conjugated meningococcal A and C vaccines
pdf, 575kb
M. Ramsay -
Availability, safety and effectiveness of serogroup B/protein meningococcal vaccines
pdf, 952kb
R. Borrow -
Draft recommendations on the use of meningococcal vaccines
pdf, 183kb
J. Abramson
Rubella vaccination
-
Report from the Working Group
pdf, 543kb
S. Reef -
Draft recommendations on the introduction of rubella vaccine and use of combined MR vaccine
pdf, 241kb
S. Reef
Polio eradication
-
Outcomes from the Independent Monitoring Board for the Global Polio Eradication Initiative
pdf, 2.48Mb
L. Donaldson -
New breakthroughs in assuring affordable IPV options for low-income countries in the post-eradication era
pdf, 2.57Mb
R. Sutter -
SAGE IPV Working Group: potential prpoliovirus vaccine is to be considered before global certificatione-requisites if cessation of type-2 oral
pdf, 389kb
E. Miller